Answers are grounded in this paper and cite their sources.
European LeukemiaNet defines the clinical signs and symptoms (CSSs) of polycythemia vera (PV) as progressive splenomegaly, leukocytosis, thrombocytosis, inadequate hematocrit control, and cardiovascular risk factors. In PV patients receiving hydroxyurea, CSSs indicate a phenotype with higher thrombosis risk across the standard risk categories. However, the prognostic value of CSSs for thrombosis or progression to secondary myelofibrosis (SMF) or acute leukemia (AL) during second-line ruxolitinib therapy remains unknown. We assessed the incidence rate ratios (IRRs) of thrombosis and disease progression during ruxolitinib treatment, and the prognostic impact of CSSs at treatment initiation, in 254 PV patients from the PV-ARC multicenter cohort. CSSs were identified in 50.4% of patients, with similar proportions in low- and high-risk groups (50% vs 50.5%). The IRRs for thrombosis and progression to SMF/AL were 1.0 and 4.2 %p‑y, respectively. Conventional thrombotic risk categories did not predict thrombosis or progression. In contrast, CSSs were associated with higher IRRs of both thrombosis (1.8 vs 0 %p‑y, p = 0.05) and progression (6.0 vs 2.3 %p‑y, p = 0.02). Persistent or progressive leukocytosis was the strongest predictor of disease progression. In conclusion, CSSs refine conventional risk stratification by improving prediction of thrombosis and disease progression during ruxolitinib, supporting their integration into routine clinical assessment.
No takes yet. Share an insight, caveat, or question.
Palandri et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: